Progress of oncolytic virotherapy for neuroblastoma.
clinical
combination therapy
mechanism
neuroblastoma
oncolytic virus
preclinical
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
09
2022
accepted:
03
11
2022
entrez:
5
12
2022
pubmed:
6
12
2022
medline:
6
12
2022
Statut:
epublish
Résumé
As a neuroendocrine tumor derived from the neural crest, neuroblastoma (NB) is the most common extracranial solid tumor in children. The prognosis in patients with low- and intermediate-risk NB is favorable while that in high-risk patients is often detrimental. However, the management of the considerably large proportion of high-risk patients remains challenging in clinical practice. Among various new approaches, oncolytic virus (OV) therapy offers great advantages in tumor treatment, especially for high-risk NB. Genetic modified OVs can target NB specifically without affecting normal tissue and avoid the widespread drug resistance issue in anticancer monotherapy. Meanwhile, its safety profile provides great potential in combination therapy with chemo-, radio-, and immunotherapy. The therapeutic efficacy of OV for NB is impressive from bench to bedside. The effectiveness and safety of OVs have been demonstrated and reported in studies on children with NB. Furthermore, clinical trials on some OVs (Celyvir, Pexa-Vec (JX-594) and Seneca Valley Virus (NTX-010)) have reported great results. This review summarizes the latest evidence in the therapeutic application of OVs in NB, including those generated in cell lines, animal models and clinical trials.
Identifiants
pubmed: 36467495
doi: 10.3389/fped.2022.1055729
pmc: PMC9716318
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1055729Informations de copyright
© 2022 Chen, Dai, Zhan, Yang, Chen, Li, Zhou and Dong.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS Pathog. 2011 Aug;7(8):e1002240
pubmed: 21901103
Int J Interferon Cytokine Mediat Res. 2009 Dec 1;1:15-32
pubmed: 20607123
Biochem Biophys Res Commun. 2017 Sep 9;491(1):134-139
pubmed: 28711493
Rev Neurosci. 2020 Sep 14;:
pubmed: 32920543
PLoS One. 2013 Jun 10;8(6):e66825
pubmed: 23762498
Nat Biotechnol. 2012 Jul 10;30(7):658-70
pubmed: 22781695
Lancet. 2001 Feb 17;357(9255):525-6
pubmed: 11229673
Uirusu. 2001 Dec;51(2):201-8
pubmed: 11977762
PLoS One. 2018 Jul 25;13(7):e0200358
pubmed: 30044847
Viruses. 2016 Feb 04;8(2):
pubmed: 26861381
Jpn J Clin Oncol. 2018 Mar 1;48(3):214-241
pubmed: 29378002
Science. 1991 May 10;252(5007):854-6
pubmed: 1851332
Assay Drug Dev Technol. 2019 Jan;17(1):8-13
pubmed: 30657702
J Virol. 2011 Dec;85(24):13114-23
pubmed: 21957304
Br J Cancer. 2011 Nov 8;105(10):1512-21
pubmed: 21989183
J Immunol Res. 2016;2016:2568125
pubmed: 27610392
Clin Cancer Res. 2008 Jun 15;14(12):3933-41
pubmed: 18559615
Head Neck. 2008 Aug;30(8):1045-51
pubmed: 18615711
Cancer Res. 2008 Feb 15;68(4):1170-9
pubmed: 18281493
Mol Oncol. 2013 Oct;7(5):944-54
pubmed: 23816608
Cancer Res. 2007 Mar 15;67(6):2857-64
pubmed: 17363609
Oncotarget. 2017 Mar 14;8(11):17412-17427
pubmed: 28147331
Front Immunol. 2018 Dec 11;9:2909
pubmed: 30619273
Mol Ther. 2006 May;13(5):882-90
pubmed: 16569513
Cancer Metastasis Rev. 2020 Mar;39(1):261-274
pubmed: 31989509
Virol J. 2015 Jan 29;12:6
pubmed: 25630937
Cancer Lett. 2016 Feb 28;371(2):161-70
pubmed: 26655276
Mol Ther Methods Clin Dev. 2020 Jan 15;17:349-358
pubmed: 32071927
Nat Med. 2002 May;8(5):527-31
pubmed: 11984600
Nature. 2011 Aug 31;477(7362):99-102
pubmed: 21886163
J Natl Cancer Inst. 2007 Nov 7;99(21):1623-33
pubmed: 17971529
Mol Ther. 2009 Jul;17(7):1125-35
pubmed: 19367259
J Virol. 2005 Nov;79(22):14235-43
pubmed: 16254358
BMC Cancer. 2019 Oct 21;19(1):970
pubmed: 31638925
Cancer Lett. 2012 Dec 28;325(2):227-37
pubmed: 22796607
J Cell Mol Med. 2012 Jul;16(7):1435-46
pubmed: 21895963
Cancer Gene Ther. 2010 Jul;17(7):476-83
pubmed: 20168350
J Virol. 2006 Aug;80(15):7308-15
pubmed: 16840311
EBioMedicine. 2018 May;31:17-24
pubmed: 29724655
Nat Rev Microbiol. 2014 Jan;12(1):23-34
pubmed: 24292552
Biomaterials. 2018 Mar;158:86-94
pubmed: 29304405
Mol Ther. 2007 Apr;15(4):660-5
pubmed: 17264852
Gene Ther. 2004 Nov;11(22):1648-58
pubmed: 15334111
Mol Ther. 2009 Oct;17(10):1677-82
pubmed: 19672244
Mol Immunol. 1999 Sep-Oct;36(13-14):929-39
pubmed: 10698347
J Neurovirol. 2008 Jan;14(1):28-40
pubmed: 18300073
Mol Ther Oncolytics. 2020 Jun 01;18:14-23
pubmed: 32637577
Chin Clin Oncol. 2018 Apr;7(2):16
pubmed: 29764161
Int J Oncol. 2011 Jan;38(1):81-7
pubmed: 21109928
Mol Ther Oncolytics. 2019 Apr 25;13:93-106
pubmed: 31080879
J Clin Oncol. 1998 Apr;16(4):1265-9
pubmed: 9552024
Oncotarget. 2017 Jul 11;8(28):45415-45431
pubmed: 28525366
Front Oncol. 2020 Apr 16;10:475
pubmed: 32373515
Cells. 2019 Jun 20;8(6):
pubmed: 31226846
Int J Cancer. 2011 Feb 15;128(4):908-19
pubmed: 20473905
J Virol. 2008 Oct;82(20):10153-61
pubmed: 18684832
Nat Genet. 2015 Dec;47(12):1411-4
pubmed: 26523776
Hum Vaccin Immunother. 2015;11(7):1573-84
pubmed: 25996182
J Virol. 2004 Dec;78(23):13139-52
pubmed: 15542666
Front Med. 2020 Apr;14(2):160-184
pubmed: 32146606
Hum Gene Ther. 1999 Nov 20;10(17):2741-55
pubmed: 10584921
Expert Rev Anticancer Ther. 2011 Apr;11(4):525-32
pubmed: 21504319
Bone Marrow Transplant. 1999 Apr;23(8):789-95
pubmed: 10231141
Mol Ther. 2007 Sep;15(9):1607-15
pubmed: 17579575
Curr Probl Cancer. 2021 Feb;45(1):100639
pubmed: 32828575
JCO Precis Oncol. 2021 Feb 24;5:
pubmed: 34250386
Cancer Gene Ther. 2000 Jun;7(6):939-46
pubmed: 10880026
J Cancer Res Clin Oncol. 2013 Jun;139(6):933-41
pubmed: 23443256
Curr Pediatr Rev. 2018;14(2):73-90
pubmed: 29380702
J Immunother Cancer. 2018 Dec 4;6(1):140
pubmed: 30514385
Lancet Oncol. 2008 Jun;9(6):533-42
pubmed: 18495536
Mol Ther. 2010 Mar;18(3):544-51
pubmed: 20051938
Cancer. 2008 Nov 1;113(9):2575-96
pubmed: 18837040
Cancer Gene Ther. 2007 Jan;14(1):45-56
pubmed: 16990846
Mol Ther. 2020 Apr 8;28(4):1033-1042
pubmed: 32053771
Blood. 2001 Jun 15;97(12):3746-54
pubmed: 11389012
Acta Oncol. 2010;49(1):117-9
pubmed: 19735000
Front Oncol. 2017 May 23;7:106
pubmed: 28589085
Front Microbiol. 2012 Mar 01;3:75
pubmed: 22403577
Viruses. 2018 Aug 26;10(9):
pubmed: 30149659
Int J Interferon Cytokine Mediat Res. 2010 May 1;2010(2):63-72
pubmed: 20556219
Tumour Biol. 2015 Aug;36(8):6037-43
pubmed: 25736927
Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2208-13
pubmed: 10681459
Trends Immunol. 2018 Mar;39(3):209-221
pubmed: 29275092
Clin Microbiol Rev. 2016 Jul;29(3):487-524
pubmed: 27029595
Mol Ther Oncolytics. 2016 Mar 16;3:16005
pubmed: 27626059
Circ Res. 2003 May 2;92(8):827-39
pubmed: 12730128
J Virol. 1994 Aug;68(8):4963-72
pubmed: 8035495
Cell Tissue Res. 2018 May;372(2):233-243
pubmed: 28924803
Neuropathol Appl Neurobiol. 1998 Oct;24(5):367-72
pubmed: 9821167
Discov Med. 2010 Nov;10(54):387-93
pubmed: 21122470
Cancer Res. 2013 Feb 15;73(4):1265-75
pubmed: 23393196
Int J Oncol. 2004 Jan;24(1):49-58
pubmed: 14654940
JAMA Oncol. 2017 Jun 01;3(6):841-849
pubmed: 27441411
EMBO J. 1997 Jun 2;16(11):2985-95
pubmed: 9214616
Cancer Res. 1994 Nov 15;54(22):5745-51
pubmed: 7954393
Cancer Immunol Immunother. 2018 Oct;67(10):1589-1602
pubmed: 30066102
J Gene Med. 2018 May;20(5):e3015
pubmed: 29575374
Hum Vaccin Immunother. 2020 Oct 2;16(10):2389-2402
pubmed: 32078405
Pediatr Blood Cancer. 2015 May;62(5):743-50
pubmed: 25307519
J Gen Virol. 2006 Oct;87(Pt 10):2767-2779
pubmed: 16963735
Life Sci. 2001 Jan 26;68(10):1161-8
pubmed: 11228100
Clin Cancer Res. 2007 Jan 1;13(1):316-22
pubmed: 17200370
Cancers (Basel). 2020 Apr 28;12(5):
pubmed: 32354143
Neurosci Lett. 2004 Jul 8;364(3):173-8
pubmed: 15196670
Oncotarget. 2020 Jan 28;11(4):347-361
pubmed: 32064039
Pediatr Surg Int. 2015 Dec;31(12):1151-9
pubmed: 26298056
Cancer Res. 2003 May 15;63(10):2462-9
pubmed: 12750267
Mol Ther. 2011 Jun;19(6):1008-16
pubmed: 21505424
PLoS One. 2013 Oct 10;8(10):e77753
pubmed: 24130898
Sci Data. 2017 Mar 28;4:170033
pubmed: 28350380
Mol Ther Oncolytics. 2021 May 05;21:356-366
pubmed: 34141872
Exp Biol Med (Maywood). 2020 Dec;245(18):1637-1647
pubmed: 32787463
Nat Rev Immunol. 2018 Aug;18(8):498-513
pubmed: 29743717
Nature. 2015 Oct 29;526(7575):700-4
pubmed: 26466568
Curr Opin Immunol. 2018 Apr;51:83-90
pubmed: 29550660
Sci Transl Med. 2013 May 15;5(185):185ra63
pubmed: 23677592
Pediatr Blood Cancer. 2010 Aug;55(2):295-303
pubmed: 20582972
Int J Mol Sci. 2020 Oct 14;21(20):
pubmed: 33066689
J Virol. 1999 Sep;73(9):7556-64
pubmed: 10438845
J Immunother. 2016 Nov/Dec;39(9):343-354
pubmed: 27741089
Front Immunol. 2018 Oct 23;9:2460
pubmed: 30405639
Oncolytic Virother. 2016 Sep 06;5:81-9
pubmed: 27660749
J Pers Med. 2021 Aug 30;11(9):
pubmed: 34575646
Neuro Oncol. 2005 Jul;7(3):213-24
pubmed: 16053696
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545
Br J Cancer. 2009 Jan 27;100(2):352-9
pubmed: 19142187
Pediatr Blood Cancer. 2005 May;44(5):469-78
pubmed: 15570577
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371
Emerg Infect Dis. 2016 Jul;22(7):1185-92
pubmed: 27070380
Gene Ther. 2016 Feb;23(2):135-43
pubmed: 26583803
Int J Cancer. 2010 Sep 1;127(5):1230-9
pubmed: 20087864
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6803-8
pubmed: 10841575
Mol Cancer Ther. 2019 Jan;18(1):127-138
pubmed: 30322950
Mol Ther. 2015 Mar;23(3):602-8
pubmed: 25531693
Mol Cancer Ther. 2006 Mar;5(3):755-66
pubmed: 16546991
Hum Gene Ther. 2000 Nov 1;11(16):2219-30
pubmed: 11084679
Gene Ther. 2007 Jul;14(13):1045-54
pubmed: 17429445